About Akeso Biomedical
Akeso Biomedical is a private company based in Burlington, Massachusetts. It has reported $5,452,925 raised in eight offerings on Form D since April 2014. Its chief executive is Simon Williams.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 29, 2023 | Jun 6, 2023 | $25,000of $200K target | 2 | $12,500 | Equity, DebtRule 506(b) | Form D ↗ |
| Feb 5, 2021 | Feb 12, 2021 | $573,905of $1.0M target | 30 | $19,130 | EquityRule 506(b) | Form D ↗ |
| Oct 28, 2019 | Nov 8, 2019 | $597,325of $3.0M target | 20 | $29,866 | EquityRule 506(b) | Form D ↗ |
| May 12, 2018 | May 18, 2018amended Dec 5, 2018 | $981,695of $2.5M target | 51 | $19,249 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 31, 2016 | Mar 23, 2016amended Mar 17, 2017 | $2,515,000of $5.0M target | 26 | $96,731 | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jul 10, 2015 | Jul 13, 2015 | $535,000of $1.0M target | 10 | $53,500 | EquityRule 506(b) | Form D ↗ |
| Dec 22, 2014 | Dec 22, 2014 | $225,000of $500K target | 9 | $25,000 | EquityRule 506(b) | Form D ↗ |
| Not yet | Apr 2, 2014 | $0of $250K target | 0 | — | EquityRule 506(b) | Form D ↗ |
| Total, eight offerings | $5,452,925 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Akeso Biomedical's Form D filed Jun 6, 2023.
GL
KO
Kevin Ohashi
Director
SW
Simon Williams
CEO and director
SR
Scott Roth
Director
RG
AS
Anthony Sinskey
Director
Earlier filings also listed R. Goforth (director, last listed Dec 2018), Mark Wagstaff (executive officer, last listed Dec 2018), Mark Kidd (executive officer, last listed Mar 2017) and Bernard Prusaczyk (director, last listed Mar 2017).